FORT WORTH, Texas--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) have surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patient ...

Alcon, Inc. (NYSE:ALC) Q4 2023 Earnings Conference Call February 28, 2024 5:30 PM ET Company Participants Daniel Cravens - Vice President and Global Head, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Ryan Zimmerman - BTIG Susannah Ludwig - Bernstein Anthony Petrone - Mizuho Group David Saxon - Needham & Company Larry Biegelsen - Wells Fargo Brett Fishbin - KeyBanc Capital Markets Tom Stephan - Stife ...

Alcon, Inc. (ALC) delivered core earnings per share (EPS) of 70 cents in the fourth quarter of 2023, up 66.7% from the year-ago quarter’s figure (up 78% at the constant exchange rate or CER). The figure topped the Zacks Consensus Estimate by 2.9%. Alcon’s “core” results are based on non-IFRS (International Financial Reporting Standards) measures.In the fourth quarter, the company’s diluted EPS was 86 cents compared to a loss of 20 cents per share in the prior-year quarter.For the full year, the core EPS was ...

For the quarter ended December 2023, Alcon (ALC) reported revenue of $2.33 billion, up 8.2% over the same period last year. EPS came in at $0.70, compared to $0.42 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.34 billion, representing a surprise of -0.22%. The company delivered an EPS surprise of +2.94%, with the consensus EPS estimate being $0.68.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they com ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve months ended December 31, 2023. For the fourth quarter of 2023, sales were $2.3 billion, an increase of 8% on a reported basis and 10% on a constant currency basis(1), as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.86 and core diluted earnings per share(2) of $0.70 in the fourth quarter of 2023. David J. Endicott, Alco ...

Core Insights - Alcon is facing significant cost pressures due to inflation in electronic components, freight, labor, resins, and plastics, which are negatively impacting the company's margins [1] - The ophthalmology industry is highly competitive, with Alcon encountering challenges from both large manufacturers and small specialized producers, as well as alternative medical therapies from pharmaceutical companies [1][2] - In the vision care segment, Alcon is experiencing intense competition, particularly in the contact lens market, where new entrants from Asia are threatening market share [2] Group 1: Surgical Business - Alcon's Surgical business benefits from a diverse portfolio and ongoing innovation, with one in three intraocular lens (IOL) implants globally being Alcon products, and one in two premium lenses being Alcon's [3] - The company's flagship lenses, Vivity and PanOptix, are leading in the U.S. and globally, with expansion opportunities in markets like China [3] Group 2: Vision Care Business - Alcon is achieving solid growth in its Vision Care segment, driven by strong sales of contact lenses and ocular health products, outpacing market growth in new product categories [4] - The company is seeing increased interest in specialty lenses, including multifocal and toric options, with successful clinical outcomes reported for its DAILIES Total1 product line [4]

ALCON INC. INTERIM FINANCIAL REPORT | INDEX | Page | | --- | --- | | Operating Performance | 2 | | Liquidity and Capital Resources | 11 | | Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) | | | Consolidated Income Statement | 15 | | Consolidated Statement of Comprehensive Income/(Loss) | 16 | | Consolidated Balance Sheet | 17 | | Consolidated Statement of Changes in Equity | 18 | | Consolidated Statement of Cash Flows | 19 | | Notes to Condensed Consolidated Interim Financial S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F | ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | OR | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 | | | OR | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ | OR ☐ ...

Analysts on Wall Street project that Alcon (ALC) will announce quarterly earnings of $0.68 per share in its forthcoming report, representing an increase of 61.9% year over year. Revenues are projected to reach $2.34 billion, increasing 8.5% from the same quarter last year.The current level reflects a downward revision of 0.5% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both COMET-2 and COMET-3, which enrolled more than 930 dry eye subjects in total (randomized 1:1 to AR-15512 or vehicle control), the primary endpoint o ...